A new mechanistic link has been identified between the expression of initiator methionine tRNA and cancer progression, whereby elevated levels of this tRNA specifically drive synthesis of secretome components, resulting in a type II collagen-rich matrix that promotes tumour progression.
Protein synthesis from mRNAs is a highly regulated three-stage process composed of initiation, elongation and termination steps. Global control of mRNA translation makes a considerable contribution to the overall regulation of gene expression [1] . Current data suggest that the initiation stage involving the recruitment of the small ribosomal subunit to the mRNAa process coordinated by the eukaryotic initiation factor (eIF) 4F complex -is the rate-limiting step of translation [2] ( Figure 1 ). Protein synthesis is controlled by regulating the formation of both the eIF4F complex and the ternary complex, which comprises eIF2, GTP and the initiator methionine tRNA (tRNA i Met ).
Dysregulation of mRNA translation is associated with tumorigenesis and it is well established that this can occur via increased expression of eIFs [3] [4] [5] . More recently, the cellular tRNA composition has also been shown to have dramatic effects on cell growth. For example, it has been demonstrated that increased synthesis of specific proteins, particularly in a tumour cell, is directly related to tRNA content. Thus, tRNAs induced in proliferating cells were shown to have anticodons corresponding to codon usage signatures characteristic of proliferation-related genes [6] . Given the relative abundance of tRNA i Met [7, 8] and the fact that it is necessary for the initiation of the translation of all transcripts ( Figures 1 and 2 ), it could be hypothesised that there would also be message-specific differences in the requirement for this tRNA, in a similar manner to the requirement of eIFs. An exciting new study published in this issue of Current Biology from Clarke et al. [9] has now shown that upregulation of tRNA i Met promotes tumour growth and angiogenesis. This is due to increased synthesis of subsets of mRNAs that encode part of the secretome and are required for the generation of the extracellular matrix (ECM), including specific types of collagen.
Clark et al. [9] demonstrated that immortalised human mammary carcinomaassociated fibroblasts (CAFs), which are known to promote tumour cell growth and angiogenesis, had significantly increased expression of both tRNA Met levels, the translation of the secretome and tumorigenesis that has important implications for the diagnosis and treatment of a range of cancer types. These new findings provide an interesting twist on previous work involving therapeutic targeting of the unfolded protein response (UPR), which regulates cellular adaptation to the accumulation of unfolded proteins within the endoplasmic reticulum (ER). In the tumour cell environment, activation of the UPR has been shown to be associated with both tumour cell survival and tumour progression [10] . UPR activation is achieved by phosphorylation of the ER For initiation of translation, eIF4F complex and ternary complex associate with the 40S ribosomal subunit and form the translation-competent, 43S pre-initiation complex. The eIF4F complex is composed of the large scaffold protein eIF4G that has binding sites for the cap-binding protein eIF4E, which interacts with the 7 methyl G cap structure at the 5' end of the mRNA, and for eIF4A, an RNA helicase required to unwind regions of structure that would otherwise impede the scanning ribosome [2] . In addition, eIF4G has binding sites for eIF3, which is required to recruit the ribosome. The interaction of poly A binding protein (PABP), which binds to the poly A tail at the 3' end of the mRNA, with the amino-terminal region of eIF4G and with eIF4B (which binds to and stimulates the activity of eIF4A) allows circularisation and stablilisation of this large complex. The small ribosomal subunit, as part of a pre-initiation complex containing the ternary complex (eIF2, GTP and methionyl-tRNAi (tRNA i Met )) and eIF1, eIF1A and eIF5, interacts with the mRNA bound by the eIF4F complex. The pre-initiation complex then scans along the 5' UTR of the mRNA until it recognises an initiation codon, AUG, which is complementary to the anticodon of tRNAi Upon start site recognition, the eIF2-bound GTP present in the ternary complex (also containing tRNA i Met ) is hydrolysed to GDP and tRNA i Met is uncoupled from eIF2. In order to be recycled, eIF2 is recharged with GTP by the guanine nucleotide exchange factor (GEF) eIF2B. However, when eIF2 is phosphorylated on its a subunit by eIF2a kinases, it becomes a competitive inhibitor of eIF2B, which prevents eIF2 recycling and reduces translation initiation rates by lowering ternary complex concentration and inhibiting start codon recognition [12] .
R242 Current Biology 26, R229-R246, March 21, 2016 ª2016 Elsevier Ltd All rights reserved Current Biology Dispatches kinase PERK, which then decreases ternary complex levels and consequently inhibits global protein synthesis (Figure 2) . It has been suggested in a number of studies (such as [11] ) that PERK inhibition and a reduction in UPR activation would be a mechanism by which tumour cells could be sensitised to anti-cancer therapeutics [10] . Indeed, PERK inhibitors in animal models have been shown to exhibit both anti-tumour and anti-angiogenic activity [11] . It is also likely that the demands made on the tumour cell in order to translate components of the secretome, including collagen II, would similarly activate the UPR pathway. However, PERK inhibition under these conditions would release the block on ternary complex production and could enhance the translation of mRNAs that are particularly dependent upon tRNA i
Met levels or the ternary complex for their initiation, including the ECM components described [9] , thereby promoting rather than inhibiting tumorigenesis. The new study by Clarke et al. [9] therefore reveals that a much greater understanding of the nature of the cancer to be treated is required if drugs that have been developed to target PERK and other components of the UPR are to have clinical use in cancer chemotherapy.
